CN111909203B - 一种三苯胺-三苯基膦类化合物及其制备方法和应用 - Google Patents
一种三苯胺-三苯基膦类化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN111909203B CN111909203B CN202010652913.7A CN202010652913A CN111909203B CN 111909203 B CN111909203 B CN 111909203B CN 202010652913 A CN202010652913 A CN 202010652913A CN 111909203 B CN111909203 B CN 111909203B
- Authority
- CN
- China
- Prior art keywords
- triphenylamine
- triphenylphosphine
- compound
- tpa
- tpp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Triphenylamine-triphenylphosphine compound Chemical class 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 12
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 3
- 150000002367 halogens Chemical class 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 14
- 239000011259 mixed solution Substances 0.000 claims description 13
- 239000004305 biphenyl Substances 0.000 claims description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 9
- 239000004327 boric acid Substances 0.000 claims description 9
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 8
- 238000004440 column chromatography Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 4
- ODHXBMXNKOYIBV-UHFFFAOYSA-N triphenylamine Chemical compound C1=CC=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 ODHXBMXNKOYIBV-UHFFFAOYSA-N 0.000 claims description 4
- SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 claims description 3
- SQTLUXJWUCHKMT-UHFFFAOYSA-N 4-bromo-n,n-diphenylaniline Chemical compound C1=CC(Br)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 SQTLUXJWUCHKMT-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 29
- 201000011510 cancer Diseases 0.000 abstract description 29
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 27
- 239000001301 oxygen Substances 0.000 abstract description 27
- 229910052760 oxygen Inorganic materials 0.000 abstract description 27
- 238000002428 photodynamic therapy Methods 0.000 abstract description 16
- 125000004429 atom Chemical group 0.000 abstract description 8
- 230000002438 mitochondrial effect Effects 0.000 abstract description 8
- 230000005284 excitation Effects 0.000 abstract description 6
- 230000006907 apoptotic process Effects 0.000 abstract description 5
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical group C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 230000009977 dual effect Effects 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 3
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 230000010354 integration Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 210000003470 mitochondria Anatomy 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000012043 crude product Substances 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- UOLLTMLEYKZJEC-UHFFFAOYSA-N N,N-diphenylaniline triphenylphosphane Chemical class C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=CC=CC=C3.C1=CC=C(C=C1)P(C2=CC=CC=C2)C3=CC=CC=C3 UOLLTMLEYKZJEC-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000006617 triphenylamine group Chemical group 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- XCVSDCPWJRHMSZ-UHFFFAOYSA-M [6-(diethylamino)-9-[2-(4-methyl-2-oxochromen-7-yl)oxycarbonylphenyl]xanthen-3-ylidene]-diethylazanium;chloride Chemical compound [Cl-].C1=CC(=[N+](CC)CC)C=C2OC3=CC(N(CC)CC)=CC=C3C(C=3C(=CC=CC=3)C(=O)OC=3C=C4OC(=O)C=C(C)C4=CC=3)=C21 XCVSDCPWJRHMSZ-UHFFFAOYSA-M 0.000 description 2
- 238000010226 confocal imaging Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- NQFBCRWFMDVQQK-UHFFFAOYSA-N N,N-diphenyl-2-pyridin-4-ylaniline Chemical compound N1=CC=C(C=C1)C1=C(C=CC=C1)N(C1=CC=CC=C1)C1=CC=CC=C1 NQFBCRWFMDVQQK-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1014—Carbocyclic compounds bridged by heteroatoms, e.g. N, P, Si or B
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E10/00—Energy generation through renewable energy sources
- Y02E10/50—Photovoltaic [PV] energy
- Y02E10/549—Organic PV cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域
本发明涉及光动力治疗技术领域,更具体地,涉及一种三苯胺-三苯基膦类化合物及其制备方法和应用。
背景技术
癌症发病率逐年提高,并且死亡率也一直高居不下。光动力治疗是一种新兴的癌症治疗方式,这种方式具备微创、高靶向性和低抗药性等优点,光动力治疗主要依靠在光照条件下,光敏剂可以产生活性氧,从而诱导癌症细胞凋亡和组织破坏。
中国专利CN107722055B公开了一种低功率白光驱动的线粒体靶向荧光探针光敏剂,该荧光探针光敏剂表面修饰的靶向分子能够靶向细胞内的线粒体,能进行线粒体荧光成像标记,而且用低功率(4mW/cm-2)白光作为激发光源,能在线粒体中释放活性氧进行光动力治疗,但是由于癌细胞处于乏氧环境,该荧光探针光敏剂仅依靠将氧气转化为活性氧的光动力治疗方法抗癌效果不够显著。
发明内容
本发明要解决的技术问题是克服现有单纯依靠光动力治疗的抗癌效果不够显著的缺陷和不足,提供一种三苯胺-三苯基膦类化合物,同时具备光动力治疗和线粒体介导癌细胞凋亡双重抗癌功能,这种协同抗癌作用不仅保留了光动力治疗的优势,还显著提高了抗癌效果,弥补了光动力治疗的不足。
本发明的另一目的是提供一种三苯胺-三苯基膦类化合物的制备方法。
本发明的又一目的是提供一种三苯胺-三苯基膦类化合物的应用。
本发明上述目的通过以下技术方案实现:
一种三苯胺-三苯基膦类化合物,具有如式(Ⅰ)所示分子结构:
其中R为氢、卤素、甲氧基、氧二苯基中的一种。
本发明制得三苯胺-三苯基膦类化合物在聚集状态下,三苯胺结构旋转受阻,因此当分子吸收激发光的能量时,该类化合物会以荧光的形式将能量释放出来,导致了荧光敏化的现象,使其具有聚集诱导发光性能(AIE性能),在聚集态或固态条件下具有优异的发光性质,不会出现浓度猝灭现象,可用于癌症治疗的荧光成像领域。其次,本发明的三苯胺-三苯基膦类化合物为给电子-吸电子结构(D-A结构)或带有多个重原子(卤素原子),分子中的三苯胺结构为较强的电子给体,吡啶基团为很强的电子受体,这种D-A结构可以促进系间穿越,在一定的激发光下能将氧气转换成活性氧(ROS),实现光动力治疗,而重原子可以诱发分子的重原子效应,重原子可以延长三重态寿命,在一定的激发光下可以将能量从激发态转移到三线态(即促进系间穿越),将周围的氧气转换成活性氧,过量的活性氧会导致癌细胞的死亡,从而实现光动力治疗。除此之外,本发明的三苯胺-三苯基膦类化合物为离子型化合物,还可以利用线粒体介导癌细胞凋亡,具体地,三苯胺-三苯基膦类化合物中带有正电荷和三苯基膦结构,三苯基膦结构可以靶向癌细胞内的线粒体,三苯胺基团和三苯基膦基团中的正电荷可以中和线粒体内的负电荷,干扰线粒体内外电荷,最终导致线粒体产生腺嘌呤核苷三磷酸(ATP)的能力下降,将氧气转化为活性氧的能力上升,所产生的过量的ROS可以靶向杀死癌细胞,从而实现治疗癌症的目的,综上所述,本发明的三苯胺-三苯基膦类化合物同时具备光动力治疗和线粒体介导癌细胞凋亡的双重抗癌功能,从而显著改善了抗癌效果。另一方面,由于癌细胞内的活性氧含量要远远大于正常细胞,而活性氧有很强的氧化性,本发明的分子中的离子键在癌细胞内会更容易被氧化,导致分子构象发生变化,荧光信号也随之变化,所合成的分子在正常细胞和癌细胞中会显示出不同颜色的荧光,从而达到了细胞阶段的癌症诊断的目的。因此,本发明的三苯胺-三苯基膦类化合物具有诊疗一体的效果。
优选地,所述R为氢、溴、甲氧基中的一种。
本发明保护上述三苯胺-三苯基膦类化合物的制备方法,包括如下步骤:
S1.将三苯胺类化合物和4-吡啶硼酸通过suzuki反应制得三苯胺-吡啶类化合物;所述三苯胺类化合物为4,4,4-三溴三苯胺、4-溴三苯胺或4,4-二甲醚三苯胺中的一种;
S2.将步骤S1制得的三苯胺-吡啶类化合物和(6-溴代戊基)三苯基膦通过Menshutkin反应制得式(Ⅰ)化合物。
优选地,步骤S1所述的三苯胺类化合物和4-吡啶硼酸的摩尔比为1:1~1.2。
优选地,步骤S2所述的三苯胺-吡啶类化合物和(6-溴代戊基)三苯基膦的摩尔比为1:1.1~1.15。
优选地,步骤S1为将三苯胺类化合物和4-吡啶硼酸溶解于有机溶剂中,以碳酸钾和四(三苯基膦)钯作为催化剂,在85~95℃反应8~12h,再通过柱层析法提纯制得三苯胺-吡啶类化合物。
优选地,所述有机溶剂为体积比为1:1的甲醇和四氢呋喃混合溶液。
具体地,步骤S1的反应方程式如下:
优选地,步骤S2所述的(6-溴代戊基)三苯基膦(1,6-TPP)的制备方法为将三苯基膦和1,6-二溴己烷通过Menshutkin反应制得。
具体地,所述(6-溴代戊基)三苯基膦的制备反应方程式如下:
优选地,步骤S2为将三苯胺-吡啶类化合物和(6-溴代戊基)三苯基膦溶解于有机溶剂中,在100~120℃反应60~72h,再用乙醚、甲醇和四氢呋喃混合溶液重结晶,制得式(Ⅰ)化合物。
优选地,所述的有机溶剂为乙腈。
具体地,步骤S2的反应方程式如下:
本发明还保护上述的三苯胺-三苯基膦类化合物在制备荧光探针光敏剂和/或抗癌药物中的应用。
与现有技术相比,本发明的有益效果是:
本发明的三苯胺-三苯基膦类化合物为给电子-吸电子结构(D-A结构)或带有多个重原子,能够促进系间穿越,在一定波长的激发光下能将氧气转化为活性氧,可实现光动力治疗;另外,本发明的三苯胺-三苯基膦类化合物中还含有三苯基膦基团和三苯胺基团,带有正电荷,可靶向癌细胞的线粒体,并促使其将氧气转化为活性氧的能力提高,使其具有协同抗癌作用,综上,本发明的三苯胺-三苯基膦类化合物同时具备光动力治疗和线粒体介导癌细胞凋亡双重抗癌功能,而且还具有AIE性能,具有较好的荧光特性,可实现诊疗一体,可用于制备荧光探针光敏剂,或者应用于制备抗癌药物等领域。
附图说明
图1为实施例1制得的化合物(6-溴代戊基)三苯基膦(1,6-TPP)的1HMNR图。
图2为实施例1制得的化合物4-4-二苯醚-4-溴-三苯胺(OPY-TPA-Br)的1HMNR图。
图3为实施例1制得的化合物4-4-二苯醚-4-吡啶-三苯胺(OPY-TPA-PY)的1HMNR图。
图4为实施例2制得的化合物4-4-二溴-4-吡啶基-三苯胺(Br-TPA-PY)的1HMNR图。
图5为实施例3制得的化合物4-吡啶基-三苯胺(TPA-PY)的1HMNR图。
图6为实施例4制得的化合物4-4-二甲氧基-4吡啶基-三苯胺(MeO-TPA-PY)的1HMNR图。
图7为实施例1制得的化合物4-4-二苯醚-4-吡啶基-三苯胺-(6–溴己基)-三苯基膦(OPY-TPA-TPP)的1HMNR图。
图8为实施例2制得的化合物4-4-二溴-4-吡啶基-三苯胺-(6–溴己基)-三苯基膦(Br-TPA-TPP)的1HMNR图。
图9为实施例3制得化合物4-吡啶基-三苯胺-(6–溴己基)-三苯基膦(TPA-TPP)的1HMNR图。
图10为实施例4制得化合物4-4-二甲氧基-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(MeO-TPA-TPP)的1HMNR图。
图11(A1)~(A3)、(B1)~(B3)、(C1)~(C3)分别为实施例2~4制得的4-4-二溴-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(Br-TPA-TPP)、4吡啶基-三苯胺-(6–溴己基)-三苯基膦(TPA-TPP)、4-4-二甲氧基-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(MeO-TPA-TPP)的共聚焦共染成像、商业染色剂(Mito-green和Mito-red)的共聚焦共染成像、以及化合物和商业染色剂混合后的共聚焦共染成像。
图12(A)(B)(C)为实施例2~4制得的3种化合物4-4-二溴-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(Br-TPA-TPP)、4-吡啶基-三苯胺-(6–溴己基)-三苯基膦(TPA-TPP)、4-4-二甲氧基-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(MeO-TPA-TPP)分别在癌细胞(Hela)中的共聚焦成像;图12(A1)(B1)(C1)为3种化合物4-4-二溴-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(Br-TPA-TPP)、4吡啶基-三苯胺-(6–溴己基)-三苯基膦(TPA-TPP)、4-4-二甲氧基-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(MeO-TPA-TPP)分别在正常细胞(NIH-3T3)的共聚焦成像。
图13为实施例1~4合成的四种分子(OPY-TPA-TPP,Br-TPA-TPP,TPA-TPP和MeO-TPA-TPP)分别与DCFH在白光照(150mW/cm2)射下,随着照射时间的延长(0~540s)的荧光比率变化图。
图14为实施例1~4合成的四种分子(OPY-TPA-TPP,Br-TPA-TPP,TPA-TPP和MeO-TPA-TPP)的AIE性质检测图。
实施例1
一种三苯胺-三苯基膦类化合物名称为4-4-二苯醚-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(OPY-TPA-TPP),具有如下所示分子结构:
上述OPY-TPA-TPP的制备方法,包括如下步骤:
S1.将三苯基膦(10mmol,2.62g)和1,6-二溴己烷(20mmol,4.86)混合在四氢呋喃(100mL)中,在120℃条件下反应72小时,得到产物白色粘稠状粗品(6–溴己基)-三苯基膦(1,6-TPP);用乙醚洗涤3次后,粘稠状的产物固化,用四氢呋喃、甲醇和正己烷三种混合溶剂重结晶,得到白色晶体1,6-TPP(5mmol,2.53g,产率50%)(其核磁结果如图1所示);
其反应方程式如下:
将4,4,4-三溴三苯胺(5mmol,2.41g)与4-硼酸基二苯醚(10mmol,2.14g),四三苯基磷钯(0.25mmol,288.75mg)和碳酸钾(10mmol,1.38g)加入到混合在体积比为1:1的甲醇和四氢呋喃的混合溶液中溶解,在氮气保护下90℃反应24h得到粗品4-4-二苯醚-4溴-三苯胺(OPY-TPA-Br)(其核磁结果如图2所示),通过柱层析法提纯,得到淡黄色固体,固体有淡淡的蓝色荧光,产率为55%;
其反应方程式如下:
将4-4-二苯醚-4溴-三苯胺(OPY-TPA-Br)(988mg,1.5mmol)与4-吡啶硼酸3mmol,369mg)四三苯基磷钯(0.075mmol,86mg)和碳酸钾(1.5mmol,192mg)溶解在在体积比为1:1的甲醇和四氢呋喃的混合溶液中,在氮气保护下90℃反应36h得到4,4-二苯醚-4-吡啶-三苯胺粗品,通过柱层析法提纯,得到淡黄色固体,固体有蓝色荧光,产率为75%(其核磁结果如图3所示);
其反应方程式如下:
S2.将4,4-二苯醚-4-吡啶-三苯胺(789mg,1.2mmol)与1,6-TPP(1mmol,506mg)溶解在乙腈当中,在100℃反应72小时,制得粗品4-4-二苯醚-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(OPY-TPA-TPP),粗品为橙红色粘稠状液体,用乙醚洗涤三次固化稠状液体,用正己烷、甲醇和四氢呋喃混合溶液重结晶,得到橙红色结晶状固体,固体有极强橙红色荧光,产率为15%(其核磁结果如图7所示)。
其反应方程式如下:
实施例2
一种三苯胺-三苯基膦类化合物名称为4-4-二溴-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(Br-TPA-TPP),具有如下所示分子结构:
上述Br-TPA-TPP的制备方法,包括如下步骤:
S1.将4,4,4-三溴三苯胺(5mmol,2.41g)、4-吡啶硼酸(3mmol,3.69g)、四三苯基磷钯(0.15mmol,173.3mg)和碳酸钾(3mmol,414mg)混合在体积比为1:1的甲醇和四氢呋喃的混合溶液中,通在氮气保护下90℃反应24h得到4-4-二溴-4吡啶基-三苯胺(Br-TPA-PY)粗品(其核磁结果如图4所示),通过柱层析法提纯,得到淡黄色固体,固体拥有淡淡的蓝色荧光,产率为35%;
其反应方程式如下:
S2.将Br-TPA-PY(1mmol,506mg)与1,6-三苯基膦(480g/mol,1.2mmol)溶解在乙腈(100mL)当中,在100℃反应72小时,制得粗品4-4-二溴-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(Br-TPA-TPP),粗品为黄色粘稠状液体,用乙醚洗涤三次固化稠状液体,用正己烷、甲醇和四氢呋喃混合溶液重结晶,得到黄色结晶状固体,固体有极强黄色荧光,产率为15%(其核磁结果如图8所示)。
其反应方程式如下:
实施例3
一种三苯胺-三苯基膦类化合物名称为4-吡啶基-三苯胺-(6–溴己基)-三苯基膦(TPA-TPP),具有如下所示分子结构:
上述TPA-TPP的制备方法,包括如下步骤:
S1.将4-溴三苯胺(10mmol,3.23g)与4-吡啶硼酸混(10mmol,1.23g),四三苯基磷钯(0.5mmol,577.78mg)和碳酸钾(10mmol,1.38g)溶解在体积比为1:1的甲醇和四氢呋喃的混合溶液中,通在氮气保护下90℃反应24h得4吡啶基-三苯胺(TPA-PY)粗品(其核磁结果如图5所示),通过柱层析法提纯,得到淡黄色固体,固体拥有蓝色荧光,产率为80%;
其反应方程式如下:
S2.将TPA-PY(386mg,1.2mmol)与1,6-三苯基膦(1mmol,506mg)溶解在乙腈(100mL)当中,在100℃反应72小时,制得粗品4-吡啶基-三苯胺-(6–溴己基)-三苯基膦(TPA-TPP),粗品为黄色粘稠状液体,用乙醚洗涤三次固化稠状液体,用正己烷、甲醇和四氢呋喃混合溶液重结晶,得到黄色结晶状固体,固体拥有极强黄色荧光,产率为15%。(其核磁结果如图9所示)
其反应方程式如下:
实施例4
一种三苯胺-三苯基膦类化合物名称为4-4-二甲氧基-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(MeO-TPA-TPP),具有如下所示分子结构:
上述MeO-TPA-TPP的制备方法,包括如下步骤:
S1.将4.4-二甲醚三苯胺(5mmol,1.915g)、4-吡啶硼酸(5mmol,615mg)、四三苯基磷钯(0.25mmol,288mg)和碳酸钾(5mmol,690mg)混合在体积比为1:1的甲醇和四氢呋喃的混合溶液中,通在氮气保护下90℃反应12h通过柱层析法提纯,得到黄色固体4-4-二甲氧基-4吡啶基-三苯胺(MeO-TPA-PY)(其核磁结果如图6所示),固体拥有蓝色荧光,产率为80%;
其反应方程式如下:
S2.将4-4-二甲氧基-4吡啶基-三苯胺(1.2mmol)与1,6-三苯基膦(1mmol,506mg)溶解在乙腈(100mL)当中,在100℃反应72小时,制得粗品4-4-二甲氧基-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(MeO-TPA-TPP),粗品为红色粘稠状液体,用乙醚洗涤三次固化稠状液体,用正己烷、甲醇和四氢呋喃混合溶液重结晶,得到红色结晶状固体,固体有极强红色荧光,产率为15%(其核磁结果如图10所示)。
其反应方程式如下:
结构表征和性能检测
1、核磁分析
实施例1制得的OPY-TPA-TPP的核磁结果为(如图7所示):1HNMR(400MHz,DMSO-d6)δ8.93-8.91(d,J=8.0Hz,1H),δ8.40-8.38(d,J=8.0Hz,1H),δ8.05-8.03(d,J=8.0Hz,1H),δ7.92-7.89(m,J=12.0Hz,2H),δ7.82-7.76(m,J=24.0Hz,6H),δ7.74-7.70(m,J=16.0Hz,4H),δ7.45-7.41(d,J=16.0Hz,2H),δ7.29-7.27(d,J=8.0Hz,2H),δ7.20-7.07(M,J=52.0Hz,5.5H),δ4.48-4.51(t,J=12.0Hz,1H),δ1.88-1.87(t,J=4.0Hz,1H),δ1.53-1.51(m,J=8.0Hz,2H),δ1.34-1.30(m,J=16.0Hz,1H),1.240(s,1H)。表明实施例1合成了4-4-二苯醚-4吡啶基-三苯胺-(6–溴己基)-三苯基膦。
实施例2制得的Br-TPA-PY核磁结果为(如图8所示):1HNMR(400MHz,DMSO-d6)δ8.97-8.96(d,J=4.0Hz,1H),δ8.42-8.40(d,J=8.0Hz,1H),δ8.04-8.02(d,J=8.0Hz,1H),δ7.93-7.89(t,J=16.0Hz,2H),δ7.83-8.81(d,J=8.0Hz,1.5H),δ7.80-7.77(m,J=12.0Hz,5H),δ7.59-7.61(t,J=8.0Hz,2H),δ7.13-7.11(d,J=8.0Hz,3H),δ4.51-4.48(t,J=12.0Hz,1H),δ1.88-1.85(t,J=12.0Hz,1H),δ1.78-1.75(m,J=12.0Hz,1H),δ1.56-1.52(m,J=16.0Hz,2H),δ1.36-1.28(m,J=32.0Hz,1H)。表明实施例2合成了4-4-二溴-4吡啶基-三苯胺-(6–溴己基)-三苯基膦。
实施例3制得的TPA-TPP核磁结果为(如图9所示):1HNMR(400MHz,DMSO-d6)δ8.93-8.91(d,J=8.0Hz,1H),δ8.37-8.35(d,J=8.0Hz,1H),δ8.01-7.99(d,J=8.0Hz,1H),δ7.90-7.89(d,J=4.0Hz,1.5H),δ7.82 -7.78(m,J=16.0Hz,6H),δ7.45 -7.42(t,J=8.0Hz,2H),δ7.26 -7.19(m,J=28.0Hz,3H),δ6.98 -6.96(d,J=8.0Hz,1H),δ4.48 -4.45(t,J=12.0Hz,1H),δ1.87-1.84(t,J=12.0Hz,1H),δ1.73(s,1H),δ1.51(s,1H),δ1.30(s,1H)。表明实施例3合成了4-吡啶基-三苯胺-(6–溴己基)-三苯基膦。
实施例4制得的MeO-TPA-TPP核磁结果为(如图10所示):1HNMR(400MHz,DMSO-d6)δ8.90-8.88(d,J=8.0Hz,1H),δ8.32-8.31(d,J=4.0Hz,1H),δ7.97-7.95(d,J=8.0Hz,1.5H),δ7.91-7.79(m,J=48.0Hz,8H),δ7.21-7.18(d,J=12.0Hz,2H),δ7.03-7.01(d,J=8.0Hz,2H),δ6.78-6.97(d,J=8.0Hz,1H),δ4.48-4.45(t,J=12.0Hz,1H),δ3.78(s,3H),δ1.85-1.83(d,J=8.0Hz,1H),δ1.52(s,2H),δ1.30(s,1H),δ1.24(s,1H)。表明实施例4合成了4-4-二甲氧基-4吡啶基-三苯胺-(6–溴己基)-三苯基膦。
2、三苯胺-三苯基膦类化合物AIE性质的研究
通过对实施例1~4制得的三苯胺-三苯基膦类化合物的AIE性能进行测试,将化合物溶解于良溶剂(DMSO)中,再不断滴加不良溶剂(乙醚),发现随着不良溶剂体积分数的增加,荧光比率增加,化合物溶液的荧光有明显敏化的现象,说明化合物都具备典型的AIE性质(如图14所示)。并且在仅有良溶剂存在的情况下,溶液几乎没有荧光。测试结果表明实施例1~4制得的三苯胺-三苯基膦类化合物都具备AIE性质。具备AIE性质的主要是因为在聚集状态下,阻碍的三苯胺上苯环的旋转与振动,使得能量由原来的以动能形式释放转换成光能形式释放。
3、三苯胺-三苯基膦类化合物线粒体介导性能的研究
如图11所示,将实施例2~4制得三苯胺-三苯基膦类化合物与市售商业荧光探针(mito-red和mito-green)、以及三苯胺-三苯基膦类化合物-市售商业荧光探针的混合物分别对癌细胞(Hela)进行共染,商业荧光探针与所合成的荧光分子具有很高的重合度,因此实施例2~4所合成的分子都具备良好的线粒体靶向性。
4、三苯胺-三苯基膦类化合物光动力治疗性能研究
4-4-二苯醚-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(OPY-TPA-TPP)、4吡啶基-三苯胺-(6–溴己基)-三苯基膦(TPA-TPP)、和4-4-二甲氧基-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(MeO-TPA-TPP)这三种分子都为典型的D-A结构,D-A结构可以促进系间穿越,使能量更容易达到三重态,将荧光探针光敏剂周围的氧气转换成活性氧。4-4-二溴-4-吡啶基-三苯胺-(6–溴己基)-三苯基膦(Br-TPA-TPP)虽然不是典型的D-A结构,但是分子上两个溴为重原子,会产生重原子效应,延长三重态寿命,也会使周围的氧气转换成活性氧。为了验证这四种分子产生活性氧的能力,用活性氧荧光探针(DCFH-DA)为指示剂,在白光(150mW/cm2)不同照射时间(0~540s)的条件下观察荧光强度的变化,以判断四种分子产生活性氧的能力。
结果发现,随着光照时间的增强,在所合成三苯胺-三苯基膦类化合物存在的条件下,DCFH-DA的荧光有明显变强的趋势(如图13所示),表明活性氧含量增加,表明实施例1~4的三苯胺-三苯基膦类化合物都具备很强的产生活性氧能力,可以作为非常好的光动力治疗的荧光探针光敏剂。
5、三苯胺-三苯基膦类化合物的抗肿瘤能力研究
在暗条件下,分别在癌细胞(Hela细胞模型)内加入16μM 4-吡啶基-三苯胺-(6–溴己基)-三苯基膦(TPA-TPP)、4-4-二溴-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(Br-TPA-TPP)和4-4-二甲氧基-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(MeO-TPA-TPP),癌细胞大量死亡,癌细胞存活率分别为52%、60%和39%,暗条件下,分别在正常细胞96孔板内分别加入16μM 4-吡啶基-三苯胺-(6–溴己基)-三苯基膦(TPA-TPP)、4-4-二溴-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(Br-TPA-TPP)和4-4-二甲氧基-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(MeO-TPA-TPP),正常细胞(NiH-3T3细胞模型)几乎不死亡,正常细胞存活率分别为79%、70%和75%。因为相比于癌细胞,正常细胞内含有更少的ROS,因此ROS含量的增加并不会引起正常细胞的死亡,说明实施例2~4制得的化合物具有线粒体介导癌细胞凋亡的能力。
在光照条件下,分别在癌细胞内分别加入16μM4-吡啶基-三苯胺-(6–溴己基)-三苯基膦(TPA-TPP)、4-4-二溴-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(Br-TPA-TPP)和4-4-二甲氧基-4吡啶基-三苯胺-(6–溴己基)-三苯基膦(MeO-TPA-TPP),癌细胞死亡比例进一步增加,癌细胞存活率分别为27%、45%和17%。分别在正常细胞内加入TPA-TPP、Br-TPA-TPP和MeO-TPA-TPP,正常细胞存活率依旧很高,分别为75%、90%和90%。由此可知实施例2~4制备的化合物具备良好的光动力治疗能力。
6、三苯胺-三苯基膦类化合物在肿瘤细胞和正常细胞的成像研究
如图12(A)~(C)所示,三苯胺-三苯基膦类化合物在肿瘤细胞中的荧光成像,黄光蓝移变成绿光,红光蓝移变成橙光。但是当所合成的分子进入正常细胞时,如图12(A1)~(C1)所示,荧光波长不会发生变化,未发生蓝移,呈现正常的黄光和红光。这是由于癌细胞内的超氧自由基含量比正常细胞高,相比于正常细胞,化合物进入到癌细胞内部,其离子键会更容易被氧化,且本发明制备的三苯胺-三苯基膦类化合物具备线粒体靶向和带正电荷,进入到线粒体内部时,会破坏线粒体的呼吸作用,导致产生ATP的能力下降,产生ROS的能力上升,使得细胞内活性氧含量进一步上升,加速了离子键的氧化,导致分子构象发生改变,最终导致荧光蓝移。
显然,本发明的上述实施例仅仅是为清楚地说明本发明所作的举例,而并非是对本发明的实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明权利要求的保护范围之内。
Claims (10)
2.根据权利要求1所述的三苯胺-三苯基膦类化合物,其特征在于,所述R为氢、溴、甲氧基中的一种。
3.权利要求1或2所述的三苯胺-三苯基膦类化合物的制备方法,其特征在于,包括如下步骤:
S1.将三苯胺类化合物和4-吡啶硼酸通过suzuki反应制得三苯胺-吡啶类化合物;所述三苯胺类化合物为4-4-二苯醚-4-溴-三苯胺、4,4,4-三卤代三苯胺、4-溴三苯胺或4,4-二甲醚三苯胺中的一种;
S2.将步骤S1制得的三苯胺-吡啶类化合物和(6-溴代戊基)三苯基膦通过Menshutkin反应制得式(Ⅰ)化合物。
4.根据权利要求3所述的制备方法,其特征在于,步骤S1所述的三苯胺类化合物和4-吡啶硼酸的摩尔比为1:1~1.2。
5.根据权利要求3所述的制备方法,其特征在于,步骤S2所述的三苯胺-吡啶类化合物和(6-溴代戊基)三苯基膦的摩尔比为1:1.1~1.15。
6.根据权利要求3所述的制备方法,其特征在于,步骤S1为将三苯胺类化合物和4-吡啶硼酸溶解于有机溶剂中,以碳酸钾和四(三苯基膦)钯作为催化剂,在85~95℃反应8~12h,再通过柱层析法提纯制得三苯胺-吡啶类化合物。
7.根据权利要求6所述的制备方法,其特征在于,所述有机溶剂为体积比为1:1的甲醇和四氢呋喃混合溶液。
8.根据权利要求3所述的制备方法,其特征在于,步骤S2所述的(6-溴代戊基)三苯基膦为将三苯基膦和1,6-二溴己烷通过Menshutkin反应制得。
9.根据权利要求3所述的制备方法,其特征在于,步骤S2为将三苯胺-吡啶类化合物和(6-溴代戊基)三苯基膦溶解于有机溶剂中,在100~120℃反应60~72h,再用乙醚、甲醇和四氢呋喃混合溶液重结晶,制得式(Ⅰ)化合物。
10.权利要求1或2所述的三苯胺-三苯基膦类化合物在制备荧光探针光敏剂和/或抗癌药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010652913.7A CN111909203B (zh) | 2020-07-08 | 2020-07-08 | 一种三苯胺-三苯基膦类化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010652913.7A CN111909203B (zh) | 2020-07-08 | 2020-07-08 | 一种三苯胺-三苯基膦类化合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111909203A CN111909203A (zh) | 2020-11-10 |
CN111909203B true CN111909203B (zh) | 2023-04-25 |
Family
ID=73227636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010652913.7A Active CN111909203B (zh) | 2020-07-08 | 2020-07-08 | 一种三苯胺-三苯基膦类化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111909203B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113582917B (zh) * | 2021-08-12 | 2024-05-10 | 广东工业大学 | 一种三苯胺-季铵盐型聚合物及其制备方法和应用 |
CN113788783B (zh) * | 2021-10-12 | 2023-08-22 | 江南大学 | 一种自报告光敏剂及其制备方法和应用 |
CN114656502A (zh) * | 2022-03-18 | 2022-06-24 | 华东理工大学 | 一类水溶性聚集诱导发光光敏剂及其制备方法 |
-
2020
- 2020-07-08 CN CN202010652913.7A patent/CN111909203B/zh active Active
Non-Patent Citations (1)
Title |
---|
"The AIE-Active Dual-Cationic Molecular Engineering: Synergistic Effect of Dark Toxicity and Phototoxicity for Anticancer Therapy";Yucheng Ma等;《Adv. Funct. Mater》;20210909;第31卷;第1-9页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111909203A (zh) | 2020-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111909203B (zh) | 一种三苯胺-三苯基膦类化合物及其制备方法和应用 | |
Yang et al. | Thienopyrrole-expanded BODIPY as a potential NIR photosensitizer for photodynamic therapy | |
Liu et al. | A class of wavelength-tunable near-infrared aza-BODIPY dyes and their application for sensing mercury ion | |
Bellier et al. | Thiophene-substituted aza-bodipy as a strategic synthon for the design of near-infrared dyes | |
Paitandi et al. | Pyrazole appended quinoline-BODIPY based arene ruthenium complexes: their anticancer activity and potential applications in cellular imaging | |
Rananaware et al. | Precise aggregation-induced emission enhancement via H+ sensing and its use in ratiometric detection of intracellular pH values | |
Li et al. | A glutathione-activatable photodynamic and fluorescent imaging monochromatic photosensitizer | |
Yang et al. | Highly effective thieno [2, 3-b] indole-diketopyrrolopyrrole near-infrared photosensitizer for photodynamic/photothermal dual mode therapy | |
CN108727256A (zh) | 一种基于三苯胺多吡啶盐的光敏剂及其制备方法与应用 | |
Tan et al. | Carbazole-based highly solid-state emissive fluorene derivatives with various mechanochromic fluorescence characteristics | |
Babu et al. | Synthesis, characterization and photodynamic activity of Sn (IV) triarylcorroles with red-shifted Q bands | |
Zhang et al. | Highly efficient near-infrared BODIPY phototherapeutic nanoparticles for cancer treatment | |
Li et al. | Facile fabrication of AIE/AIEE-active fluorescent nanoparticles based on barbituric for cell imaging applications | |
CN112094263B (zh) | 基于喹喔啉的D-A-π-A型有机光敏剂及其合成方法和应用 | |
Singh et al. | BODIHY based novel AIEgens and directive role of σ–spacers on their reversible mechanochromism | |
Zhou et al. | TPE-containing amphiphilic block copolymers: synthesis and application in the detection of nitroaromatic pollutants | |
Wang et al. | Intermolecular hydrogen-bond-assisted solid-state dual-emission molecules with mechanical force-induced enhanced emission | |
CN108558788A (zh) | 一种新型具有聚集诱导发光现象的荧光染料合成方法 | |
Fan et al. | 2D luminescent metal–organic framework: efficient and highly selective detection of 2, 4, 6-trinitrophenol at the ppb level | |
CN110642882B (zh) | 一种兼具双氧水检测和光动力杀伤癌细胞活性的荧光探针及其制备方法和应用 | |
Zhang et al. | A series of tetraphenylethene-based benzimidazoles: syntheses, structures, aggregation-induced emission and reversible mechanochromism | |
Hu et al. | Perylene imide derivatives: Structural modification of imide position, aggregation caused quenching mechanism, light-conversion quality and photostability | |
Tan et al. | Accessing conjugated and twisted structures for efficient dual-state emission fluorophore and its sensitive lysosomal imaging | |
Li et al. | Near-infrared absorbing aza-BODIPYs with 1, 7-di-tert-butyl groups by low-barrier rotation for photothermal application | |
Huang et al. | New thermally stable cyano-substituted D–A–π–A–D molecules with aggregation-induced emission and large two-photo absorption cross-sections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |